New radioactive tracer could sharpen breast cancer scans
NCT ID NCT05226663
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a new radioactive tracer called [18F]FluorThanatrace can improve PET/CT scans in 36 people with breast cancer. The tracer is designed to highlight an enzyme linked to cancer growth. Participants will receive the tracer before their standard surgery or biopsy, and researchers will compare the scan results with tissue samples to see if the tracer accurately spots cancer activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]FluorThanatrace (a radioactive tracer)
What this could lead to
If successful, this could lead to a more precise imaging method to detect breast cancer activity, helping doctors tailor treatments.
What could go wrong
This is a small, early-phase trial with only 36 participants. The tracer may not reliably show enzyme activity in all patients, and results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Siteman Cancer Center at Washington University
St Louis, Missouri, 63110, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States